Unicycive Therapeutics, Inc. — Form D
Unicycive Therapeutics, Inc. of LOS ALTOS, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-03-13. The offering totals $30.2M, of which $30.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-03-13
- Form: D
- Accession: 0001213900-23-019602
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $30.2M
- Amount sold: $30.2M
- Investors: 20
- Date of first sale: 2023-03-03
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-475696
Issuer
- Name: Unicycive Therapeutics, Inc.
- CIK: 0001766140
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS, CA, 94022
- Phone: 650-351-4495
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Brigitte Schiller | Director | Los Altos, CA |
| Gaurav Aggarwal | Director | Palo Alto, CA |
| John Ryan | Director | Coeur d'Alene, ID |
| Sandeep Laumas | Director | Greenwich, CT |
| Sara Kenkare-Mitra | Director | Los Altos, CA |
| John Townsend | Executive Officer | San Diego, CA |
| Shalabh Gupta | Director | Los Altos, CA |
| Shalabh Gupta | Executive Officer | Los Altos, CA |
Other filings by this issuer (4)
More